Foundation News

European Commission approves Takeda’s HYQVIA

In the news today, the European Commission approves Takeda’s HYQVIA, a new maintenance therapy for patients with CIDP. The Foundation advocates for access to all products at all points of care. As always, the Foundation recommends consulting with your physician when exploring new treatment options. We will share additional information as it becomes available.

Press Release: https://www.takeda.com/newsroom/newsreleases/2024/Takedas-HYQVIA-Approved-by-European-Commission-as-Maintenance-Therapy-in-Patients-with-Chronic-Inflammatory-Demyelinating-Polyneuropathy-CIDP/?fbclid=IwAR0X9FLKzZba7fCKlXbwzPkCpIjW9HvUVmYREkB3lSJxhqg0v7H4yHN8zVo